Q3 2026 Highlights1
- Group revenue of
US$245 million increased 19% over the prior corresponding quarter (Q3 2025) driven by continued strong demand for the commercial portfolio, in line with expectations. September sales drove a higher quarterly exit rate indicating continued strength in underlying demand forTelix's PSMA products. Precision Medicine revenue ofUS$201 million , increased 30% over the prior corresponding quarter, driven by both Gozellix® and Illuccix®2.Telix's commercial PSMA-PET imaging3 portfolio continued to strengthen its market position, driven by strong demand for our clinically differentiated products.U.S. Food and Drug Administration (FDA ) approved Pixclara®4 for glioma imaging, marking a significant milestone and establishing the first approved imaging agent for this indication in theU.S .5. The first commercial doses were administered inSeptember 2026 6.- BiPASS®, a Phase 3 study evaluating pre-biopsy prostate cancer detection, completed enrollment7, with the
FDA supporting an NDA pathway and granting Fast Track Designation8. Telix announced a merger with Isotope Technologies Munich SE (ITM). The merger creates a leading radiopharmaceutical platform with one of the industry's broadest therapeutics pipelines, supported by best-in-class isotope production, manufacturing, and supply chain capabilities9.Telix reaffirmed that FY 2026 revenue and other income is expected to be in excess ofUS$1 billion , with revenue tracking in line with upper end of FY 2026 guidance ofUS$950 million toUS$970 million plusUS$40 million of other income. The Company has also revised its FY 2026 R&D expenditure guidance range toUS$240 million toUS$260 million .
Q3 2026 Revenue
| Revenue (US$M) | Q3 2026 | Q3 2025 | % Change | Q2 2026 | % Change |
| Group revenue | 245 | 206 | 19% | 247 | (1)% |
| 201 | 155 | 30% | 202 | —% | |
| TMS revenue11 | 44 | 47 | (6)% | 45 | (2)% |
Executive Commentary
Dr.
Therapeutics Business Unit
- TLX591-Tx (177Lu rosopatamab tetraxetan): Following
FDA review and alignment of the Part 1 safety data,Telix is finalizing its IND amendment to theFDA to support progression to Part 2 of the ProstACT Global Phase 3 study in theU.S .12. Outside theU.S ., Part 2 of the global study continues to enroll patients across seven countries:Australia ,New Zealand ,Canada , Türkiye, theUK ,Singapore , andSouth Korea . Regulatory approvals have also been obtained to proceed inChina andJapan 13. - TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA): OPTIMAL-PSMA14, a Phase 2 study evaluating TLX597-Tx in metastatic androgen pathway modulator-resistant (mAPMR) prostate cancer15, completed enrollment of 120 patients16. A data readout is expected in the first half of 2027. OPTIMAL-e17, a Phase 2 study evaluating TLX597-Tx in metastatic androgen pathway modulator-naive or -sensitive (mAPMN/S) prostate cancer18, continues to demonstrate strong enrollment momentum.
- TLX250-Tx (177Lu girentuximab tetraxetan): Continued enrollment of patients in LUTEON19, a pivotal trial of TLX250-Tx in advanced clear cell Renal Cell Carcinoma (ccRCC). The trial is evaluating the safety and efficacy of TLX250-Tx compared with the investigator’s choice of monotherapy consistent with standard of care.
- TLX101-Tx (iodofalan 131I): Following full enrollment of the first cohort in Part 1 of the Phase 3 IPAX BrIGHT study20, an IND amendment was filed with the
FDA to support expansion of the trial into Part 1b in theU.S . IPAX-221, a Phase 1 study of TLX101-Tx in patients with newly diagnosed glioblastoma met its primary endpoint, establishing a maximum tolerated dose (MTD) of two 5 GBq cycles in combination with standard of care. No dose-limiting toxicities were observed, supporting advancement of IPAX-2 to Phase 222.
Precision Medicine Business Unit
68Ga-PSMA-11 for prostate cancer imaging:
- BiPASS®, a Phase 3 study of 68Ga-PSMA-11 PET in combination with MRI for the diagnosis of prostate cancer in the pre-biopsy setting, completed enrollment of 350 patients. Rapid enrollment underscores the unmet need for a minimally invasive option for prostate cancer diagnosis. The study builds on the clinical foundation established by the PRIMARY23 and PRIMARY224 studies and is intended to support regulatory submissions. The
FDA has supported an NDA pathway that could facilitate reimbursement and granted Fast Track Designation, which may enable an expedited review. - With enrollment complete in the Phase 3 registrational study of TLX591-Px (Illuccix) in
Japan 25,Telix is preparing for NDA submission and potential market entry. A Conditional Approval is currently under review byJapan's Pharmaceutical and Medical Devices Agency (PMDA) and is expected to facilitate an expedited review process.
TLX101-Px (floretyrosine F 18) for brain cancer imaging:
Telix's Marketing Authorization Application (MAA) for Pixlumi®26 inEurope remains under review.- Following the
FDA clearance of the IND application,Telix is advancing a Phase 3 registrational study to support expansion of the Pixclara label for the diagnosis of brain metastases.
TLX250-Px, Zircaix®27 (89Zr-girentuximab senvedoxam) for kidney cancer imaging:
- Following receipt of the corrected Complete Response Letter (CRL),
Telix is finalizing its Biologics License Application (BLA) resubmission package, addressing the remaining third-party manufacturing observations. Resubmission to theFDA is planned in the near term and remains a top priority for the Company in 2026.
Telix Manufacturing Solutions (TMS)
- Through RLS,
Telix has established a growing network of micro-pharmacy sites, known as UroOncRx™, providing urologists with onsite access to our imaging agents, particularly in underserved and remote markets. Multiple sites are now operational and dispensing product, further strengthening our radiopharmacy infrastructure and expanding patient access. - ARTMS, a
Telix company, has secured contracts for 50 QUANTM® Irradiation Systems (QIS®) globally, achieving a key commercial milestone and reflecting continued demand for its isotope production technology. Telix announced a collaboration with Ekalia28, a joint venture between IBA (Ion Beam Applications S.A., EURONEXT) andFramatome , to advance scalableU.S . production of astatine-211 (211At), an alpha-emitting radioisotope being investigated for targeted alpha therapy. The first IBA alpha-beam cyclotron installation at Telix’s RLS Radiopharmacies site inTrevose nearPhiladelphia (PA) is intended to establish a reproducible production model, with the potential for further rollout across the RLS network as demand develops. The collaboration secures long-term, priority isotope access for Telix’s alpha therapy pipeline, while also supporting third-party academic and industry programs.
Corporate Updates
Telix announced a transformational merger with ITM, the world's leading supplier of therapeutic radioisotopes, reinforcing its long-term strategy as a vertically integrated radiopharmaceutical company and further strengthening one of the industry's broadest therapeutic pipelines. ITM brings a complementary late-stage portfolio led by ITM-11 (177Lu-edotreotide) for gastroenteropancreatic neuroendocrine tumors (GEP-NETs), as well as industry-leading isotope capabilities anchored by the only globally scaled commercial-grade 177Lu production platform. The transaction includes upfront consideration ofUS$1.65 billion on a cash-free, debt-free basis, with ITM shareholders expected to receive approximatelyUS$1.25 billion inTelix shares released as ADRs. Additional contingent consideration of up toUS$700 million may be paid upon achievement of future regulatory approvals and commercial sales milestones for ITM-11. The transaction remains subject toTelix shareholder approval and customary closing conditions. A General Meeting of Shareholders is expected to be held onDecember 1, 2026 (AEDT) .- Mr.
David Gill was appointed Chair of the Board onSeptember 1, 2026 29.Mr. Gill is a life sciences executive with more than 35 years of experience in biopharma, radiopharmaceuticals and medical devices. He has held senior leadership positions, including President, Chief Operating Officer and Chief Financial Officer roles at multiple public companies, and brings extensive expertise in capital markets, governance, business scaling and corporate strategy. He currently serves on the boards of several healthcare companies and holds degrees fromWake Forest University andEmory University . - Mr.
Marcin Firek will joinTelix as Company Secretary, effectiveOctober 21, 2026 .Mr. Firek brings extensive experience in corporate governance, legal affairs, risk management and public company administration, including for dual-listed Australian andU.S . companies. Most recently, he served as Head of Enterprise & Operational Risk at PwC Australia. Previously, he led the Company Secretary team at Woolworths Group Limited, ASX Limited and James Hardie Industries Plc. Earlier in his career, he practiced corporate and M&A law atMinterEllison .Mr. Firek will be the primary person responsible for communications with the ASX under ASX Listing Rule 12.6. Mr. Shomalin Naidoo has also ceased his appointment as interim Company Secretary effective today.
FY 2026 guidance
Telix expects FY 2026 revenue and other income to exceedUS$1 billion , with revenue tracking toward the upper end of its FY 2026 guidance ofUS$950 million toUS$970 million , includingUS$40 million in other reported income.- Revenue guidance reflects product sales in markets where marketing authorization has been granted, includes a full-year contribution from RLS, and incorporates anticipated sales of Pixclara.
Telix revises its FY 2026 R&D expenditure guidance range toUS$240 million toUS$260 million , previouslyUS$230 million toUS$270 million , subject to the achievement of planned clinical, regulatory and development milestones.
About
| Investor Relations Annie.kasparian@telixpharma.com Charlene.jaw@telixpharma.com | Media Eliza@schleifsteinpr.com |
This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors.
Guidance Disclaimer
The stated revenue guidance is based on expected global and domestic economic conditions and is subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. As such, investors are cautioned not to place undue reliance on this guidance and in particular
Key variables that could cause actual results to differ materially include: the success and timing of research and development activities; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation, regulation, or policy that affects product production, distribution, pricing, reimbursement, access or tax; acquisitions and divestitures; research collaborations; litigation or government investigations; and Telix’s ability to protect its patents and other intellectual property. See the Legal Notices section below for additional information, risks and assumptions.
Legal Notices
Cautionary Statement Regarding Forward-Looking Statements.
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX),
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of
This announcement may contain forward-looking statements, including within the meaning of the
Trademarks and
©2026
| _____________________________________________ 1 The financial information for the quarter ended 2 Illuccix® (kit for the preparation of gallium-68 gozetotide injection). Gozellix® (kit for the preparation of gallium-68 gozetotide injection). 3 Imaging of prostate-specific membrane antigen with positron emission tomography. 4 Pixclara® (floretyrosine F 18). 5 Telix ASX disclosure 6 7 Telix ASX disclosure 8 Telix ASX disclosure 9 Telix ASX disclosure 10 Primarily sales of Illuccix and Gozellix in our 11 Telix Manufacturing Solutions (TMS) third-party revenue predominantly driven by RLS Radiopharmacies (RLS), excludes Illuccix and Gozellix sales and TMS inter-segment revenue. 12 Telix ASX disclosure 13 Telix ASX disclosure 14 Australian New Zealand Clinical Trials Registry ID: ACTRN12625000971437. 15 Formerly known as metastatic castration-resistant prostate cancer (mCRPC). 16 Telix LinkedIn 17 Australian New Zealand Clinical Trials Registry ID: ACTRN12626000034336. 18 Formerly known as metastatic hormone-sensitive prostate cancer (mHSPC). 19 ClinicalTrials.gov ID: NCT07197580. 20 ClinicalTrials.gov ID: NCT07100730. 21 ClinicalTrials.gov ID: NCT05450744 22 23 Emmett et al. Eur Urol. 2021. 24 Buteau et al. Lancet Oncol. 2026. ClinicalTrials.gov ID: NCT05154162. 25 26 Brand name subject to final regulatory approval. 27 Brand name subject to final regulatory approval. 28 29 Telix ASX disclosure |
Source: 